CRP and cancer: Moreover, treatment with doxorubicin leading to a systemic and local inflammation in cancer patients, partially due to cytosolic damages several organs like liver and heart; doxorubicin exposure in liver increased the production of circulating IL-1-β, IL-6 and hs-CRP (hypersensitive-C-reactive-protein) leading to increased risk of cardiovascular and metabolic diseases [45].